Search Results - inflammatory+disorders

25 Results

Sort By:

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

Profiling of Interferon signaling to diagnose autoimmune disorders

Unmet Need / Invention Novelty: Diagnosing an autoimmune disease using standard laboratory tests is challenging and often requires secondary validation due to high rates of false positives and overlapping biological signatures with other diseases. There is a critical need for an improved method to detect autoimmune disease signatures in tissue collected...

Published: 5/9/2024 | Inventor(s): Livia Casciola-Rosen, Antony Rosen, John Hall

Keywords(s): Autoimmune Diseases, Basic Research Biomarker, Biomarker, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, In Vitro Research Tool, Inflammatory Disorders, Research Instrument

Category(s): Technology Classifications > Research Tools, Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Autoimmunity

Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof

Unmet NeedMore than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and to enhance transplant survival. However, current immunosuppressive drugs are administered systemically and have several dose-limiting side effects...

Published: 5/9/2024 | Inventor(s): Giorgio Raimondi, Joel Schneider, Poulami Majumder

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Inflammatory Disorders, Therapeutic Matter, Therapeutics, Tissue/organ transplant rejection

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...

Published: 5/9/2024 | Inventor(s): Jordan Green, Jamie Spangler, Stephany Tzeng, Kelly Rhodes, Giorgio Raimondi, Marcos Iglesias Lozano, Jakub Tomala, Derek VanDyke, Randall Meyer

Keywords(s): Autoimmune Diseases, Biologics, Discovery/Research Tools, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Recombinant Proteins, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Cell Therapies

Cationic Biodegradable Polymer Compositions of Biomimetic Particles including Artificial Antigen Presenting Cells

Unmet NeedOver the past decade, a myriad of immune cell therapies based on the infusion of allogeneic immune cells into patients have been tested and progressed in clinical applications. Despite continual advances, immune cell therapy via antigen presenting cells is relatively expensive and time consuming, so biomimetic materials have been applied to...

Published: 5/9/2024 | Inventor(s): Jordan Green, Jonathan Schneck, Alyssa Kosmides Galaro, Randall Meyer, John Hickey, Kelly Rhodes

Keywords(s): Autoimmune Diseases, Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics, Whole cell

Category(s): Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Autoimmunity

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 5/9/2024 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Targeting TSC2 S1366 (mouse, rat) S1365 (human) by gene engineering or phosphorylation to Regulate mTOR Signaling Cascades for Therapeutic Indications

Unmet NeedThe mechanistic target of rapamycin complex-1 (mTORC1) coordinates cellular processes and regulates recycling pathways in order to control cell growth and metabolic homeostasis. Additionally, in immune cells when the T-cell receptor is activated, the mTORC1 signaling pathway is also engaged and thus plays an important role in T-cell activation,...

Published: 5/9/2024 | Inventor(s): David Kass, Kristen Kokkonen, Brittany Dunkerly-Eyring, Mark Ranek

Keywords(s): Disease Indication, Inflammatory Disorders, Target, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets

Screening Method to Identify Scleroderma Immune Responses with Anti-cancer Activity, and Induction of such Immune Responses for Cancer Therapy

Unmet NeedEpidemiological studies have shown that patients with scleroderma, a type of autoimmune rheumatic disease affecting the skin and connective tissues, have an increased risk of developing cancer relative to the general population. The exact etiology of scleroderma is still unknown. The Scleroderma Foundation estimates about 100,000 to 300,000...

Published: 5/9/2024 | Inventor(s): Ami Shah, Livia Casciola-Rosen, Antony Rosen, Takeru Igusa, Marikki Laiho

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Inflammatory Disorders, Risk Stratification, Scleroderma, Skin Disorders, Skin Fibrosis, Therapeutic Matter, Therapeutic Substance, Therapeutics

Discovery of Novel Compounds that Enhance Enteric Nervous System Function

Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...

Published: 5/9/2024 | Inventor(s): David Hackam, Peng Lu, Chhinder Sodhi

Keywords(s): Agonists/Promoters, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Inflammation > Necrotizing Enterocolitis

C34 triols in the treatment or prevention of inflammatory disorders in children and adults with a focus on necrotizing enterocolitis

Unmet Need Necrotizing enterocolitis (NEC) is the leading cause of death and disability in premature infants. The disease is characterized by a bacterial infection in the intestines that quickly progresses to organ death if untreated. Current treatment of NEC entails surgically removing the diseased parts of the intestine. However, this procedure leads...

Published: 5/9/2024 | Inventor(s): David Hackam, Chhinder Sodhi, Peter Wipf

Keywords(s): Antagonists/Inhibitors, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Inflammation > Necrotizing Enterocolitis, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

1 2 3